8-K: Relmada Therapeutics Prices $100M Offering

Relmada Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expected to raise approximately $100 million in gross proceeds.

Summary

• Relmada Therapeutics priced an underwritten public offering of 40,142,000 shares of common stock at $2.20 per share.
• The offering also includes pre-funded warrants to purchase up to 5,315,000 shares of common stock at an offering price of $2.199 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
• The gross proceeds to Relmada from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
• The net proceeds from the offering are expected to be approximately $100 million, after deducting underwriting discounts and commissions and other estimated offering expenses, and are intended for working capital and general corporate purposes.
• Company insiders, including the Chief Executive Officer, Chief Financial Officer, and certain other officers and members of the board of directors, will be purchasing approximately $2.6 million of common stock in the offering at the public offering price.

Sentiment

Score: 7

Explanation: The successful pricing of a $100 million offering with institutional and insider participation is a positive development for a clinical-stage biotech company, providing necessary capital for R&D. The dilution from the offering is a common trade-off for growth in this industry.

Positives

• The successful pricing of a $100 million offering provides significant capital to fund the company's operations and development pipeline.
• Participation by institutional investors, including Janus Henderson Investors, Ferring Ventures SA, Squadron Capital Management, Marshall Wace, Spruce Street Capital, OrbiMed, Columbia Threadneedle Investments, and Driehaus Capital Management, demonstrates market confidence.
• Company insiders purchasing approximately $2.6 million of common stock in the offering at the public price signals strong internal belief in the company's prospects.
• The capital infusion will support critical activities such as clinical studies, regulatory approvals, and further development of product candidates NDV-01 and sepranolone.

Negatives

• The issuance of 40,142,000 shares of common stock and pre-funded warrants to purchase an additional 5,315,000 shares will result in dilution for existing shareholders.

Risks

• The company's ability to complete the offering is subject to market conditions and other factors.
• Forward-looking statements are subject to risks and uncertainties, such as those detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Prospectus Supplement.
• The enforceability of agreements may be limited by bankruptcy, insolvency, reorganization, moratorium, or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.

Future Outlook

The company intends to use the net proceeds from the offering, along with existing cash, for working capital and general corporate purposes, including funding clinical studies for regulatory approvals, developing product candidates (NDV-01 and sepranolone), and exploring potential investments, acquisitions, or licensing activities related to its technologies and emerging technologies.

Management Comments

• Relmada is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

Industry Context

As a clinical-stage biotechnology company, Relmada Therapeutics' capital raise is a common and necessary step to fund ongoing research and development, particularly for clinical studies and regulatory approvals of its lead candidates, NDV-01 and sepranolone. The participation of institutional investors and company insiders in this offering suggests a degree of confidence in the company's pipeline and strategic direction within the competitive biotech landscape.

Related Party Transactions

• Company insiders, including the Chief Executive Officer, Chief Financial Officer, and certain other officers and members of the board of directors, are purchasing approximately $2.6 million of common stock in the offering at the same public offering price as other investors.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and pre-funded warrants. However, the capital raise provides funding for future growth and development, which could benefit long-term shareholder value.
• Employees: The capital raise supports the company's ongoing operations and development activities, potentially ensuring job security and continued progress on product candidates.
• Customers (future): Funding for clinical studies and product development aims to bring new therapies to market, benefiting future patients.
• Creditors: The capital raise strengthens the company's financial position, potentially reducing credit risk.

Next Steps

• Closing of the offering, expected on November 5, 2025.
• Application of net proceeds for working capital and general corporate purposes, including clinical studies, regulatory approvals, and product candidate development.
• Potential investments in or acquisitions of synergistic companies/technologies.
• Licensing activities related to current and future product candidates.
• Development of emerging technologies.
• Compliance with a 90-day lock-up period for the company and certain insiders regarding further stock sales.

Key Dates

Recommendation

The successful pricing of a significant capital raise is a positive for Relmada Therapeutics, providing essential funding for its clinical-stage pipeline. Insider participation also signals confidence. However, the immediate impact of dilution from the offering, combined with the inherent risks of a clinical-stage biotechnology company (e.g., clinical trial outcomes, regulatory approvals), suggests a 'hold' recommendation. Investors should monitor the progress of NDV-01 and sepranolone and the effective deployment of the raised capital for future catalysts.

Keywords

Relmada Therapeutics, RLMD, Underwritten Offering, Common Stock, Pre-Funded Warrants, Capital Raise, Biotechnology, Clinical-Stage, Oncology, Central Nervous System, SEC Filing, Form 8-K, Jefferies, Leerink Partners, Mizuho Securities